HALIFAX, March 23 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid
diagnostic solutions, announced today that it has filed a provisional patent
application for a system which enables over-the-counter (OTC) home testing and
diagnosis of infectious diseases, such as HIV, hepatitis C, and other medical
conditions. MedMira's comprehensive OTC system is all-inclusive, containing
everything necessary to obtain definitive test results and support the
consumer, with confidential counselling and medical referrals.
"MedMira's OTC system will enable individuals to safely and accurately
test themselves and obtain a diagnosis of diseases and medical conditions how
and when they choose," said Hermes Chan, president and COO, MedMira. "Our
system will promote public safety and customer value, and was developed based
on our first-hand OTC experience. This patent will ensure that our
intellectual property is protected as we move forward into new OTC markets,
including the United States."
MedMira was the first company in the world to introduce an OTC rapid HIV
test, in Hong Kong and Macao in 2005, and has used this experience to develop
an advanced all-inclusive, consumer-focused home diagnostic system.
Advancements in healthcare practices, particularly in the diagnostics field,
are making it possible for consumers to implement self-care solutions in the
privacy of their own home, to improve, monitor and maintain their health.
Home-use tests for infectious diseases are the next step in this self-care
evolution, and MedMira will be a global leader.
MedMira plans on introducing its home-use HIV diagnostic system in global
markets, including the United States (US), where there is increasing demand
for a home HIV testing solution. The United States Food and Drug
Administration (FDA) is currently developing requirements to support the
approval of OTC home-use HIV tests, which will allow manufacturers to bring
such tests to the US market.
Home HIV testing will be key to the control and prevention of the spread
of HIV, enabling more people to test themselves and seek treatment when
necessary. The US Centres for Disease Control and Prevention (CDC) estimates
that of the 1 million people infected with HIV in the US, approximately 25%
are unaware of their HIV status.
MedMira is the leading global manufacturer and marketer of in vitro
flow-through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
(OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
Regions, in the People's Republic of China. MiraCare(TM) is sold through
MedMira's distributor network to pharmacies, hospitals and laboratories in the
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.